In a patient with chronic pain and opioid use disorder, is there a role for Sublocade (extended‑release buprenorphine injection)?

Sublocade (Extended-Release Buprenorphine) for Chronic Pain and Opioid Use Disorder

Yes, Sublocade has a definitive role in patients with both chronic pain and opioid use disorder, providing dual benefits of addiction treatment and analgesia with superior safety compared to full opioid agonists. 1

Primary Indication and Dual Benefits

Buprenorphine should be used as first-line treatment for chronic pain in patients with opioid use disorder because it uniquely addresses both conditions simultaneously while offering a ceiling effect on respiratory depression that makes it significantly safer than hydromorphone, fentanyl, or other full agonists. 1 The Infectious Diseases Society of America explicitly recommends this approach given the critical overdose risks in this vulnerable population. 1

Evidence for Efficacy

• Systematic reviews confirm that buprenorphine provides comparable pain relief to morphine and fentanyl but with fewer adverse events. 1, 2
• Small retrospective studies demonstrate that patients taking high doses of opioids for pain experienced substantial improvements in pain and quality of life when switched from full mu opioid receptor agonists to buprenorphine. 3
• The medication reduces the likelihood of overdose death by up to threefold compared to no medication treatment. 3

Specific Clinical Scenarios Where Sublocade Excels

Complex Persistent Opioid Dependence: Buprenorphine is particularly indicated for patients who, despite substantial opioid doses, continue to manifest poor analgesia and function, yet worsen when opioids are either reduced or increased. 3 These patients typically experience prolonged symptoms from opioid reduction including hyperalgesia and anhedonia, but do not meet full criteria for OUD (they do not crave opioids or use them compulsively). 3 The US Department of Health and Human Services guide suggests a buprenorphine trial in persons failing to benefit from high opioid doses yet responding poorly to taper. 3

Practical Management Strategy for Pain on Sublocade

First-line approach: Increase the existing buprenorphine dose or add supplemental sublingual buprenorphine in divided doses (every 8 hours) for breakthrough pain. 1, 4 Dosing ranges of 4-16 mg sublingual divided into 8-hour doses have demonstrated benefit in patients with chronic noncancer pain, with improved functioning and mood. 1

Second-line approach: If maximal buprenorphine doses are reached without adequate analgesia, add a long-acting potent opioid such as fentanyl, morphine, or hydromorphone while closely monitoring the patient. 1, 4, 5 Due to buprenorphine's high binding affinity for the μ-opioid receptor, higher doses of the additional opioid may be required as buprenorphine prevents lower doses from accessing receptors. 1, 2

Multimodal adjuncts: Combine with nonopioid analgesics including NSAIDs for musculoskeletal pain, gabapentin for neuropathic pain, and topical agents as appropriate. 2, 4, 5

Critical Safety Advantages

• Buprenorphine demonstrates a ceiling effect on respiratory depression, making it significantly safer than full agonists—no cases of respiratory depression or toxicity were observed in case series of pain management with extended-release buprenorphine. 1, 2, 5
• The medication is less subject to dose escalation and may reduce urges for dose escalation in patients on high-dose opioids. 3
• For patients with any degree of renal impairment, buprenorphine is the safest opioid choice as it undergoes hepatic metabolism to inactive metabolites requiring no dose adjustment. 2

Mandatory Pre-Treatment Screening

All patients must be screened for depression before initiating long-term opioid therapy using the two-question screen and PHQ-9, as mental health significantly impacts pain outcomes and substance use risk. 1, 2 Scores ≥10 on the PHQ-9 require psychiatric referral. 1

Common Pitfalls to Avoid

• Do not discontinue Sublocade based on inadequate analgesia alone—first optimize the dose or add adjunctive therapies, as this medication provides critical dual benefits with superior safety. 1
• Do not use mixed agonist-antagonist opioids (pentazocine, nalbuphine) during treatment, as they may precipitate withdrawal. 2
• Recognize that higher doses of rescue opioids may be needed due to buprenorphine's receptor occupancy—do not assume standard opioid dosing will be effective. 1, 2
• Avoid the assumption that all deterioration from opioid reduction is due to dependence—the original pain processes likely remain active and could be unmasked by opioid reduction. 3

Barriers to Implementation

Provider bias, limited access to palliative care clinicians with addiction medicine training, and payor restrictions to adding sublingual buprenorphine for patients on extended-release formulations represent significant barriers that require advocacy and additional clinician training. 4